FDA Accepts Supplemental Application for Percodan by Endo Operations
The FDA has accepted a supplemental application for Percodan, which contains aspirin and oxycodone hydrochloride.
Published: June 24, 2026
Updated: June 24, 2026
Author: Humanexa Intelligence
Therapeutic area: Pain Management / Opioid Combination
Asset: Percodan
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Percodan
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for Percodan signifies a potential shift in the competitive landscape of the opioid pain management market. This could impact market share dynamics and necessitate strategic adjustments from competitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for further updates on the approval process and any subsequent market launch timelines.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.